Resverlogix Corp is the only Canadian recipient of the 23 2008 Technology Pioneer Awards handed out by the World Economic Forum. The Calgary-based firm was recognized for its development of new molecules used in the treatment of atherosclerosis. Cardiovascular disease (CVD) is identified as the number one cause of death globally, with more than 18 million dead annually. Current therapies address only 30% of the risk associated with CVD and Resverlogix is aiming at the 70% of those still at risk. It was chosen for the award among 273 nominees nominated by venture capital and technology companies from around the world....